Shares of Vaccitech plc (NASDAQ:VACC – Get Rating) shot up 0.4% during mid-day trading on Friday . The stock traded as high as $2.49 and last traded at $2.46. 35,486 shares traded hands during trading, an increase of 8% from the average session volume of 32,771 shares. The stock had previously closed at $2.45.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Vaccitech in a research report on Monday, November 14th.
Get Vaccitech alerts:Vaccitech Stock Up 0.4 %
The firm has a market capitalization of $91.75 million, a PE ratio of 7.69 and a beta of -0.03. The stock has a 50-day moving average price of $2.39 and a 200 day moving average price of $3.50.
Vaccitech (NASDAQ:VACC – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of ($0.32) by $0.54. The company had revenue of $6.17 million during the quarter, compared to analysts' expectations of $5.43 million. As a group, equities analysts predict that Vaccitech plc will post 0.27 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A hedge fund recently raised its stake in Vaccitech stock. M&G Investment Management Ltd. boosted its position in shares of Vaccitech plc (NASDAQ:VACC – Get Rating) by 377.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,197,349 shares of the company's stock after buying an additional 4,108,752 shares during the period. M&G Investment Management Ltd. owned 13.96% of Vaccitech worth $15,592,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.07% of the company's stock.
Vaccitech Company Profile
(Get Rating)
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
Further Reading
- Get a free copy of the StockNews.com research report on Vaccitech (VACC)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.